Traditional approaches to natural product discovery involve cell-based screening of natural product extracts followed by compound isolation and characterization. Their importance notwithstanding, continued mining leads to depletion of natural resources and the reisolation of previously identified metabolites. Metagenomic strategies aimed at localizing the biosynthetic cluster genes and expressing them in surrogate hosts offers one possible alternative. A fundamental question that naturally arises when pursuing such a strategy is, how large must the genomic library be to effectively represent the genome of an organism(s) and the biosynthetic gene clusters they harbor? Such an issue is certainly augmented in the absence of expensive robotics to expedite colony picking and/or screening of clones. We have developed an algorism, named BPC (biosynthetic pathway coverage), supported by molecular simulations to deduce the number of BAC clones required to achieve proper coverage of the genome and their respective biosynthetic pathways. The strategy has been applied to the construction of a large-insert BAC library from a marine microorganism, Hon6 (isolated from Honokohau, Maui) thought to represent a new species. The genomic library is constructed with a BAC yeast shuttle vector pClasper lacZ paving the way for the culturing of libraries in both prokaryotic and eukaryotic hosts. Flow cytometric methods are utilized to estimate the genome size of the organism and BPC implemented to assess P-coverage or percent coverage. A genetic selection strategy is illustrated, applications of which could expedite screening efforts in the identification and localization of biosynthetic pathways from marine microbial consortia, offering a powerful complement to genome sequencing and degenerate probe strategies. Implementing this approach, we report on the biotin biosynthetic pathway from the marine microorganism Hon6.

Marine microbial populations collected from the Hawaiian Islands were screened for antimicrobial activity. A blue metabolite was identified from mixed cell cultures, but production was not evident in pure cultures. Experiments designed to probe the synergistic role of the microorganisms are presented. Full characterization of the blue natural product, pyocyanin, is provided including corrections made to 1H and 13C-NMR assignments of the molecule misreported in the chemical literature and yeast transcriptome analysis. The transcriptional effects were consistent with the compound's purported role as an inducer of oxidative stress and damage and illustrates the overall potential of the method to reveal the primary biological/cellular effects of a natural product. The experiments outlined here might serve as a general paradigm for identification of natural products arising from microbial communities and investigation of their respective interactions.

Studies on the mechanism of action of the antitumor agent azinomycin B in vitro suggest that the drug elicits its lethal effects by the formation of interstrand crosslinks within the major groove of DNA. Here, we demonstrate the biological effects of the drug in vivo. Fluorescence imaging revealed localization of azinomycin B in the nuclear region of yeast. Moreover, experiments with oligonucleotide microarrays examined the effects of the drug across the yeast transcriptome. The results demonstrated a robust DNA damage response that supports the proposed role of the drug as a covalent DNA modifying agent. RT-PCR analysis validated the gene changes, and flow cytometry of azinomycin-treated yeast cells demonstrated a phenotypic S phase shift consistent with transcriptional effects.

Experiments reveal that the metabolic precursor aminoacetone is a key intermediate in the production of the antitumor agent azinomycin A relative to the structurally and functionally related agent, azinomycin B. Azinomycin A and B arise through bifurcation of the biosynthetic pathway and competition between metabolic substrates. The availability of the biosynthetic precursors in vivo, aminoacetone for azinomycin A and threonine for azinomycin B, controls the overall ratio of azinomycin A to B produced.